Safe in Pregnancy / Safe in Children
  • Safe in Pregnancy and Children

Up-to-date evidence-based information on emerging vaccines in pregnancy and childhood

Botones de Enfermedades
COVID 19
Chikungunya
Lassa Fever
Mpox
RSV
Disease X
  • COVID-19 Vaccines for Pregnant Persons

A regularly updated, comprehensive database and synthesis of published literature related to COVID-19 vaccines in pregnancy through a living systematic review and meta-analyses.

COVID-19 Vaccine Dashboard
PROSPERO Protocol

dash Pregnant persons pregnant

Pairwise Meta Analyses
Quality Assessment
Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings

Supported by the Bill & Melinda Gates Foundation (INV-008443)

Vaccine vial
Why is this relevant?

600+ million infections and over 6.5 million deaths have been recorded globally, with significant regional variations in infection and case fatality rates.

Pregnant individuals face a 2–3× higher risk of severe illness and preterm birth, while children, despite generally milder symptoms, can, despite being rare, develop Multisystem Inflammatory Syndrome (MISC).

Widely deployed mRNA and vector vaccines have markedly reduced severe outcomes, though booster campaigns remain crucial.

mosquito Aedes aegypti
Mother children chikungunya
  • CHIKUNGUNYA Vaccines for Pregnant Persons and Children

A continuously updated, thorough compilation and analysis of published and unpublished literature concerning Chikungunya vaccines during pregnancy and childhood through a living systematic review and meta-analyses.

Chikungunya Vaccine Dashboard
PROSPERO Protocols

dash Pregnant persons pregnant dash Children and adolescents boys

Pairwise and Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings
Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Why is this relevant?

Outbreaks have affected millions worldwide, with 70–80% of cases reporting debilitating joint pain and potential long-term arthritic symptoms.

Maternal infections may lead to preterm labor and neonatal complications, while children can experience prolonged recovery periods, impacting daily life.

Transmitted primarily by Aedes mosquitoes, the potential for chikungunya epidemics is high in tropical and subtropical regions.

A vaccine can help prevent infection and reduce the burden of this debilitating disease.

  • LASSA FEVER Vaccines for Pregnant Persons and Children

An ongoing, comprehensive collection and examination of published and unpublished literature on Chikungunya vaccines during pregnancy and childhood, with regular updates through a living systematic review and meta-analyses.

Lassa Fever Vaccine Dashboard
PROSPERO Protocols

dash Pregnant persons pregnant dash Children and adolescents boys

Pairwise and Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings
Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Boy showing younger brother plaster on arm
woman baby Kenya
Why is this relevant?

Lassa fever causes 100,000–300,000 infections and approximately 5,000 deaths annually in West Africa, with a 15% case fatality rate among hospitalized patients.

Pregnant individuals face an over 80% maternal and fetal mortality rate in late pregnancy, while children and adolescents suffer higher rates of severe disease.

It spreads primarily through Mastomys natalensis rats excreta, and global travel increases the risk of cases being exported beyond endemic regions.

About 20% of Lassa fever cases progress to severe conditions, such as hemorrhagic fever and multi-organ failure.

Currently, there is no approved vaccine, but promising vaccine candidates are in development.

mpox vaccination
Monkeypox lesions in the thigh of Asian, Burmese Child
  • MPOX Vaccines for Pregnant Persons and Children

An ongoing, comprehensive review and analysis of published literature on safety, efficacy, effectiveness and immunogenicity of Mpox vaccines during pregnancy and childhood, utilizing a living systematic review and meta-analysis approach.

Mpox Vaccine Dashboard
PROSPERO Protocols

dash Pregnant persons pregnant dash Children and adolescents boys

Pairwise and Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings
Quality Assessment

Supported by the Safety Platform for Emergency vACcines (SPEAC), Task Force for Global Health, Inc. – The Coalition for Epidemic Preparedness Innovations (CEPI).

Why is this relevant?

The ongoing outbreak of mpox in Africa has caused 100,000 cases, with a case fatality rate ranging from 2.8% to 4.9% in the Democratic Republic of Congo, but lower rates in other countries.

Pregnant individuals are at an increased risk for miscarriage and fetal complications, and pediatric cases may be more severe due to an immature immune response.

Transmission occurs via close contact with infected lesions, body fluids, and respiratory droplets, complicating outbreak control.

Available vaccines offer protection, and new MPOX-specific vaccines are under development.

  • RSV vaccine for pregnant persons
    Effectiveness and Inmunogenicity outcomes

As post licensure data are generated, this living systematic review aims to capture and analyze
this information and provide reliable, up-to-date global evidence to describe the effectiveness
and immunogenicity of RSVpreF vaccination in pregnancy.

RSV Vaccine Dashboard
PROSPERO Protocols

Pairwise and Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings
Quality Assessment

Sponsored by Pfizer

Why is this relevant?

RSV is a leading cause of severe lower-respiratory tract infection (LRTI) in young children worldwide—with an estimated 3.6 million LRTI hospitalizations and 100,000 deaths each year; 50% of RSV deaths among children <5 years of age occur in infants <6 months, and 97% of RSV-associated deaths occur in low- and middle-income countries

RSV prevention efforts prioritize protecting young infants through 2 approaches

  • a maternal RSV vaccine administered during pregnancy in the late second or third trimester
  • a long-acting monoclonal antibody administered as a single-dose to for newborns/infants

RSV seasonality varies by region and surges can strain pediatric services.

Understanding the real-world effectiveness and impact of RSV prevention strategies is necessary to inform implementation and national policies.

Ensuring access is critical: the majority of RSV-related deaths occur in resource-limited settings, and low-cost interventions that can be integrated into routine healthcare programs offer opportunities for implementation and acceptance.

mujeres-negras-embarazadas-posando
  • RSV vaccine for pregnant persons
    Safety outcomes

A continuous and comprehensive assessment of published data on the safety of the RSV
vaccine during pregnancy, using a living systematic review and meta-analysis approach

RSV Vaccine Dashboard
PROSPERO Protocols
Pairwise and Proportional Meta Analyses
PRISMA Flow Diagram
Summary of Findings
Quality Assessment
  • Disease X

Disease X is the name given by scientists to an unknown pathogen that could emerge in future and cause a serious international epidemic or pandemic. Disease X is included in the WHO’s updated Blueprint list of diseases for which investing in research and development should be an international
priority. It is also a priority for CEPI’s research and development investments.

Our living systematic review will provide up-to-date information on platforms and components
of vaccines used in pregnancy and childhood which could potentially be adapted to develop
new vaccines against Disease X. We will also be ready to rapidly deploy a living systematic
review of future vaccines against Disease X to protect pregnant people and children.

vaccine vial disease x
Woman and man doctors
Why is this relevant?

Represents a serious international epidemic that could be caused by a pathogen currently unknown to cause human disease.

There are ongoing efforts aimed at developing platform vaccines and broad‐spectrum antivirals to mitigate severe outcomes once an outbreak emerges.

Vulnerable groups, including pregnant individuals and children, may experience disproportionately high rates of maternal and pediatric complications, underscoring the urgency for proactive research and preparedness.

  • Safe in Pregnancy Spotlights

Spotlights

3 Videos

On October 21, Dr. Agustín Ciapponi, Director of Cochrane Argentina from the Institute for Clinical Effectiveness and Health Policy (IECS), presented the findings of “Chikungunya Vaccines: Safety, Efficacy, and Immunogenicity – A Living Systematic Review and Meta-Analysis” on the VuMedi platform, a leading educational resource for clinicians worldwide.
The session highlighted the public health relevance of chikungunya virus (CHIKV) and reviewed the most up-to-date evidence on approved vaccines, including Ixchiq®, Vimkunya®, and mRNA-1388. Dr. Ciapponi presented findings from the first living systematic review on this topic, synthesizing data on safety, immunogenicity, and efficacy, and discussed implications for vaccine use, research gaps, and future strategies.
The event generated strong interest among healthcare professionals, reflecting the growing need for evidence-based information on emerging vaccines. 

  • Contact Us

Get In Touch with Us

Andrea Meyer

Director of Global Health Research

  • Tulane University School of Public Health and Tropical Medicine
  • ameyer1@tulane.edu
Safe in Pregnancy / Safe in Children

Up-to-date evidence-based information on emerging vaccines in pregnancy and childhood.

Quick Links

Contact Us

Andrea Meyer

ameyer1@tulane.edu

Linkedin
Copyright © 2022. All rights reserved.
Safe in Pregnancy / Safe in Children
Contact Us
Contact Us